| Saham Diterbitkan | 1,261,290 shares |
| Saham Orang Dalam | 622,454 shares |
| Pemilikan Orang Dalam | 49.35 % |
| Jumlah Orang Dalam | 20 |
Skor Sentimen Orang Dalam
Skor Sentimen Orang Dalam mendapati syarikat dibeli oleh orang dalam korporat.
Ia adalah hasil daripada model kuantitatif berbilang faktor yang canggih yang mengenal pasti syarikat dengan tahap pengumpulan orang dalam yang paling tinggi. Model pemarkahan menggunakan gabungan bilangan bersih orang dalam yang membeli 90 hari sebelumnya, jumlah saham yang dibeli sebagai peratusan saham beredar, dan jumlah saham yang dimiliki oleh orang dalam. Nombor ini berjulat dari 0 hingga 100, dengan nombor yang lebih tinggi menunjukkan tahap pengumpulan yang lebih tinggi kepada rakannya, dan 50 adalah purata.
Kekerapan Kemas Kini: Harian
Skor Sentimen Pegawai
Skor Sentimen Pegawai mendapati syarikat dibeli oleh Pegawai Korporat.
Mengikut definisi Pegawai Korporat ialah Orang Dalam Korporat, tetapi tidak seperti beberapa Orang Dalam yang lain (10% Pemegang Saham dan Ahli Lembaga), Pegawai bekerja untuk syarikat tersebut setiap hari, dan mereka menggunakan wang mereka sendiri semasa berdagang . (10% Pemegang Saham dan Ahli Lembaga Pengarah selalunya pengurus dana yang menguruskan wang orang lain.) Oleh itu, dagangan orang dalam yang dibuat oleh Pegawai adalah lebih penting dan harus dilayan dengan sewajarnya.
Seperti Skor Sentimen Orang Dalam, Skor Sentimen Pegawai adalah hasil daripada model kuantitatif berbilang faktor yang canggih yang mengenal pasti syarikat yang mempunyai tahap pengumpulan pegawai tertinggi.
Kekerapan Kemas Kini: Harian
Metrik Orang Dalam Utama
Kad ini menunjukkan bagaimana kedudukan syarikat mengikut pelbagai metrik orang dalam. Kedudukan persentil menunjukkan cara syarikat ini dibandingkan dengan syarikat lain di pasaran AS. Kedudukan yang lebih tinggi menunjukkan keadaan yang lebih baik.
Sebagai contoh, adalah diterima umum bahawa pembelian orang dalam ialah penunjuk positif, jadi syarikat yang mempunyai lebih banyak pembelian orang dalam akan mendapat kedudukan lebih tinggi daripada syarikat yang kurang pembelian orang dalam (atau malah jualan orang dalam).
Peratusan Saham Beredar yang Dibeli oleh Orang Dalam (Kedudukan)
0.000 %( )
5079 out of 11244Peratusan Saham Beredar yang Dibeli oleh Orang Dalam ialah jumlah bilangan saham yang dibeli oleh orang dalam tolak jumlah bilangan saham yang dijual oleh orang dalam dalam tempoh 90 hari terakhir, dibahagikan dengan jumlah saham beredar dan didarab dengan 100.
Carta Dagangan Dalaman
Sensei Biotherapeutics, Inc. dagangan dalaman ditunjukkan dalam carta berikut. Orang dalam ialah pegawai, pengarah atau pelabur penting dalam syarikat. Secara umumnya adalah menyalahi undang-undang bagi orang dalam untuk membuat perdagangan dalam syarikat mereka berdasarkan maklumat material dan bukan awam. Ini tidak bermakna haram untuk mereka membuat sebarang perdagangan dalam syarikat mereka sendiri. Walau bagaimanapun, mereka mesti melaporkan semua dagangan kepada SEC melalui Borang 4.
Senarai Orang Dalam dan Metrik Keberuntungan
Jadual ini menunjukkan senarai orang dalam yang diketahui dan dijana secara automatik daripada pemfailan yang didedahkan kepada SEC. Sebagai tambahan kepada nama, gelaran terkini dan pengarah, pegawai, atau 10% jawatan pemilik, kami menyediakan pegangan yang didedahkan terkini. Selain itu, apabila boleh, kami menyediakan sejarah prestasi perdagangan untuk orang dalam. Sejarah prestasi perdagangan ialah purata wajaran prestasi transaksi pembelian pasaran terbuka sebenar yang dibuat oleh orang dalam. Untuk mendapatkan maklumat lanjut tentang cara ini dikira, tonton webinar YouTube ini.
See our leaderboard of most profitable insider traders.
| Orang dalam | Purata Keuntungan (%) | Saham Dimiliki |
Berpecah Dilaraskan |
|---|---|---|---|
|
Apeiron Investment Group Ltd.
10% Owner -
|
0 | 0 | |
| Samuel Broder Director - [D] | 8,932 | 447 | |
|
Cambrian BioPharma Inc
10% Owner -
|
3,653,120 | 182,656 | |
| John Celebi PRESIDENT AND CEO, Director - [D] [O] | 105,862 | 5,293 | |
| Erin Colgan CHIEF FINANCIAL OFFICER - [O] | 67,462 | 3,373 | |
| Jessie English Director - [D] | 8,932 | 447 |
| Orang dalam | Purata Keuntungan (%) | Saham Dimiliki |
Berpecah Dilaraskan |
|---|---|---|---|
| Patrick Stephen Gallagher Chief Business Officer - [O] | 34,130 | 1,706 | |
|
H&s Investments I Lp
10% Owner -
|
4,425,998 | 221,300 | |
|
H&s Ventures Llc
10% Owner -
|
4,425,998 | 221,300 | |
| Bob Holmen Director - [D] | 25,598 | 1,280 | |
| Kristian Humer Director - [D] | 8,932 | 447 | |
|
James Peyer
Director, 10% Owner -
[D]
|
3,653,120 | 182,656 | |
| Robert Hamilton Pierce Chief R&D Officer - [O] | 21,000 | 1,050 |
| Orang dalam | Purata Keuntungan (%) | Saham Dimiliki |
Berpecah Dilaraskan |
|---|---|---|---|
| Thomas G Ricks Director - [D] | 343,863 | 17,193 | |
| William R Ringo Director - [D] | 23,399 | 1,170 | |
|
Henry Samueli
10% Owner -
|
4,425,998 | 221,300 | |
|
Susan Samueli
10% Owner -
|
4,425,998 | 221,300 | |
|
Michael Schulman
10% Owner -
|
4,425,998 | 221,300 | |
| Deneen Vojta Director - [D] | 8,932 | 447 | |
| der Horst Edward van CHIEF SCIENTIFIC OFFICER - [O] | 59,794 | 2,990 |
Report errors via our new Insider Auditing Tool
Rekod Jejak Pembelian Orang Dalam - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam SNSE / Sensei Biotherapeutics, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras pecah.
Rekod Jejak Jualan Orang Dalam - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam SNSE / Sensei Biotherapeutics, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras pecah.
Sejarah Transaksi
Klik ikon pautan untuk melihat sejarah transaksi penuh. Transaksi yang dilaporkan sebagai sebahagian daripada pelan dagangan automatik 10b5-1 akan mempunyai X dalam lajur bertanda 10b-5.
| Fail Tarikh |
Dagangan Tarikh |
Borang | Orang dalam | Simbol Saham | Nama Sekuriti | Kod | Langsung | Harga Pelaksanaan |
Harga Unit |
Unit Berubah |
Nilai Berubah (1K) |
Baki Opsyen |
Baki Saham |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-26 | 2025-02-19 | 4 | Celebi John | SNSE | Common Stock | D | 0.4760 | -5,558 | -3 | 105,862 | ||||
| 2025-02-26 | 2025-02-19 | 4 | van der Horst Edward | SNSE | Common Stock | D | 0.4760 | -2,276 | -1 | 59,794 | ||||
| 2024-02-16 | 2024-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 0.7900 | -2,843 | -2 | 56,070 | ||||
| 2024-02-16 | 2024-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 0.7900 | -5,891 | -5 | 105,420 | ||||
| 2024-02-16 | 2024-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 0.7900 | -3,627 | -3 | 67,462 | ||||
| 2023-09-13 | 2023-09-11 | 4 | Celebi John | SNSE | Common Stock | D | 0.8500 | 500 | 0 | 111,311 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 1.5000 | -9,383 | -14 | 34,130 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 1.5000 | -20,492 | -31 | 110,811 | ||||
| 2023-09-11 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 1.5000 | -9,525 | -14 | 52,913 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 1.5000 | -10,943 | -16 | 68,089 | ||||
| 2023-08-02 | 2023-07-31 | 4 | Peyer James | SNSE | Common Stock | I | 1.2600 | -1,587,302 | -2,000 | 3,653,120 | ||||
| 2023-08-02 | 2023-07-31 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 1.2600 | -1,587,302 | -2,000 | 3,653,120 | ||||
| 2023-07-12 | 2023-07-10 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 4,466 | 23,399 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Broder Samuel | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Humer Kristian | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | English Jessie | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Holmen Bob | SNSE | Common Stock | D | 4,466 | 25,598 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Vojta Deneen | SNSE | Common Stock | D | 4,466 | 8,932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Peyer James | SNSE | Common Stock | I | 4,466 | 5,240,422 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,466 | 5,240,422 | ||||||
| 2023-06-02 | 2023-06-01 | 4 | Apeiron Investment Group Ltd. By Presight Sensei Co-Invest Fund, L.P. | SNSE | Common Stock | I | 1.5800 | -955,738 | -1,510 | 0 | ||||
| 2023-06-02 | 2023-06-01 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1.5800 | -2,485,923 | -3,928 | 0 | ||||
| 2023-03-29 | 2023-02-15 | 4/A | Gallagher Patrick Stephen | SNSE | Common Stock | D | 14,200 | 43,513 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Gallagher Patrick Stephen | SNSE | Common Stock | D | 29,313 | 29,313 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Celebi John | SNSE | Common Stock | D | 21,300 | 131,303 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Celebi John | SNSE | Common Stock | D | 51,893 | 110,003 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Colgan Erin | SNSE | Common Stock | D | 21,300 | 79,032 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Colgan Erin | SNSE | Common Stock | D | 30,046 | 57,732 | ||||||
| 2023-03-07 | 2022-06-10 | 4/A | Cambrian BioPharma Inc | SNSE | Restricted Stock Unit Grant | D | 4,466 | 5,235,956 | ||||||
| 2023-02-27 | 2023-02-23 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1.6023 | 1,100 | 2 | 2,485,923 | ||||
| 2023-02-27 | 2023-02-23 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1.6150 | 1,100 | 2 | 2,484,823 | ||||
| 2023-02-17 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 21,300 | 127,307 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 51,893 | 106,007 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 14,200 | 43,515 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 29,313 | 29,313 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 21,300 | 73,032 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 30,046 | 51,732 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 17,700 | 62,438 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 23,565 | 44,738 | ||||||
| 2022-12-16 | 3 | van der Horst Edward | SNSE | Common Stock | D | 21,173 | ||||||||
| 2022-08-01 | 2022-06-10 | 4/A | Peyer James | SNSE | Restricted Stock Unit Grant | I | 4,466 | 5,235,956 | ||||||
| 2022-08-01 | 3/A | Peyer James | SNSE | Common Stock | I | 2,282,827 | ||||||||
| 2022-07-20 | 3 | Presight Co-Invest Management, L.L.C. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 2,483,723 | ||||||||
| 2022-07-20 | 3 | Presight Co-Invest Management, L.L.C. By Presight Sensei Co-Invest Fund, L.P. | SNSE | Common Stock | I | 955,738 | ||||||||
| 2022-06-14 | 2022-06-10 | 4 | Cambrian BioPharma Inc | SNSE | Restricted Stock Unit Grant | D | 4,466 | 5,235,954 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Peyer James | SNSE | Restricted Stock Unit Grant | I | 4,466 | 5,235,954 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Humer Kristian | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Vojta Deneen | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | English Jessie | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Holmen Bob | SNSE | Common Stock | D | 4,466 | 21,132 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Broder Samuel | SNSE | Common Stock | D | 4,466 | 4,466 | ||||||
| 2022-06-10 | 2022-03-02 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.2000 | 1,203 | 4 | 5,231,488 | ||||
| 2022-06-10 | 2022-03-02 | 4/A | Peyer James | SNSE | Common Stock | I | 3.2000 | 1,203 | 4 | 5,231,488 | ||||
| 2022-04-21 | 2021-03-23 | 4/A | Peyer James | SNSE | Common Stock | I | 14.3400 | 9,500 | 136 | 4,798,293 | ||||
| 2022-04-21 | 2021-02-18 | 4/A | Peyer James | SNSE | Common Stock | I | 19.7500 | 752 | 15 | 4,690,905 | ||||
| 2022-04-21 | 2021-03-23 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.3400 | 9,500 | 136 | 4,798,293 | ||||
| 2022-04-21 | 2021-02-18 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19.7500 | 752 | 15 | 4,690,905 | ||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Stock Option (Right to Buy) | D | 3.08 | 29,100 | 29,100 | |||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 10,000 | 18,933 | ||||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 8,933 | 8,933 | ||||||
| 2022-03-02 | 2022-03-02 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.2000 | 1,203 | 4 | 5,231,989 | ||||
| 2022-03-02 | 2022-03-02 | 4 | Peyer James | SNSE | Common Stock | I | 3.2000 | 1,203 | 4 | 5,231,989 | ||||
| 2022-03-01 | 2022-03-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.6000 | 2,458 | 9 | 5,230,786 | ||||
| 2022-03-01 | 2022-02-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.6000 | 42 | 0 | 5,228,328 | ||||
| 2022-03-01 | 2022-03-01 | 4 | Peyer James | SNSE | Common Stock | I | 3.6000 | 2,458 | 9 | 5,230,786 | ||||
| 2022-03-01 | 2022-02-28 | 4 | Peyer James | SNSE | Common Stock | I | 3.6000 | 42 | 0 | 5,228,328 | ||||
| 2022-02-28 | 2022-02-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.6500 | 2,500 | 9 | 5,228,286 | ||||
| 2022-02-28 | 2022-02-25 | 4 | Peyer James | SNSE | Common Stock | I | 3.6500 | 2,500 | 9 | 5,228,286 | ||||
| 2022-02-24 | 2022-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.6300 | 15,000 | 54 | 5,225,786 | ||||
| 2022-02-24 | 2022-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.8000 | 2,500 | 10 | 5,210,786 | ||||
| 2022-02-24 | 2022-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 3.6300 | 15,000 | 54 | 5,225,786 | ||||
| 2022-02-24 | 2022-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 3.8000 | 2,500 | 10 | 5,210,786 | ||||
| 2022-02-22 | 2022-02-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3.9700 | 15,000 | 60 | 5,208,286 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.1700 | 4,949 | 21 | 5,193,286 | ||||
| 2022-02-22 | 2022-02-18 | 4 | Peyer James | SNSE | Common Stock | I | 3.9700 | 15,000 | 60 | 5,208,286 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Peyer James | SNSE | Common Stock | I | 4.1700 | 4,949 | 21 | 5,193,286 | ||||
| 2022-02-17 | 2022-02-15 | 4 | Pierce Robert Hamilton | SNSE | Stock Option (Right to Buy) | D | 4.30 | 62,000 | 62,000 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Pierce Robert Hamilton | SNSE | Common Stock | D | 21,000 | 21,000 | ||||||
| 2022-02-17 | 2022-02-15 | 4 | Colgan Erin | SNSE | Stock Option (Right to Buy) | D | 4.30 | 62,000 | 62,000 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 21,000 | 21,686 | ||||||
| 2022-02-17 | 2022-02-15 | 4 | Celebi John | SNSE | Stock Option (Right to Buy) | D | 4.30 | 161,600 | 161,600 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 53,900 | 54,114 | ||||||
| 2022-02-16 | 2022-02-16 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.2500 | 2,551 | 11 | 5,188,337 | ||||
| 2022-02-16 | 2022-02-14 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.1800 | 10,000 | 42 | 5,185,786 | ||||
| 2022-02-16 | 2022-02-16 | 4 | Peyer James | SNSE | Common Stock | D | 4.2500 | 2,551 | 11 | 5,188,337 | ||||
| 2022-02-16 | 2022-02-14 | 4 | Peyer James | SNSE | Common Stock | I | 4.1800 | 10,000 | 42 | 5,185,786 | ||||
| 2022-02-14 | 2022-02-11 | 4 | Peyer James | SNSE | Common Stock | I | 4.4000 | 12,500 | 55 | 5,175,786 | ||||
| 2022-02-14 | 2022-02-10 | 4 | Peyer James | SNSE | Common Stock | I | 4.5800 | 5,000 | 23 | 5,163,286 | ||||
| 2022-02-14 | 2022-02-11 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.4000 | 12,500 | 55 | 5,175,786 | ||||
| 2022-02-14 | 2022-02-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.5800 | 5,000 | 23 | 5,163,286 | ||||
| 2022-02-08 | 2022-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.3300 | 10,000 | 43 | 5,158,286 | ||||
| 2022-02-08 | 2022-02-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.4500 | 2,500 | 11 | 5,148,286 | ||||
| 2022-02-08 | 2022-02-03 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.6500 | 17,500 | 81 | 5,145,786 | ||||
| 2022-02-08 | 2022-02-08 | 4 | Peyer James | SNSE | Common Stock | I | 4.3300 | 10,000 | 43 | 5,158,286 | ||||
| 2022-02-08 | 2022-02-04 | 4 | Peyer James | SNSE | Common Stock | I | 4.4500 | 2,500 | 11 | 5,148,286 | ||||
| 2022-02-08 | 2022-02-03 | 4 | Peyer James | SNSE | Common Stock | I | 4.6500 | 17,500 | 81 | 5,145,786 | ||||
| 2022-01-31 | 2022-01-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.2200 | 8,900 | 38 | 5,128,286 | ||||
| 2022-01-31 | 2022-01-27 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.3100 | 6,100 | 26 | 5,119,386 | ||||
| 2022-01-31 | 2022-01-28 | 4 | Peyer James | SNSE | Common Stock | I | 4.2200 | 8,900 | 38 | 5,128,286 | ||||
| 2022-01-31 | 2022-01-27 | 4 | Peyer James | SNSE | Common Stock | I | 4.3100 | 6,100 | 26 | 5,119,386 | ||||
| 2022-01-27 | 2022-01-26 | 4 | Peyer James | SNSE | Common Stock | I | 4.6200 | 29,900 | 138 | 5,113,286 | ||||
| 2022-01-27 | 2022-01-25 | 4 | Peyer James | SNSE | Common Stock | I | 4.8600 | 20,100 | 98 | 5,083,386 | ||||
| 2022-01-27 | 2022-01-26 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.6200 | 29,900 | 138 | 5,113,286 | ||||
| 2022-01-27 | 2022-01-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.8600 | 20,100 | 98 | 5,083,386 | ||||
| 2022-01-25 | 2022-01-24 | 4 | Peyer James | SNSE | Common Stock | I | 4.6900 | 22,707 | 106 | 5,063,286 | ||||
| 2022-01-25 | 2022-01-21 | 4 | Peyer James | SNSE | Common Stock | I | 4.9400 | 24,703 | 122 | 5,040,579 | ||||
| 2022-01-25 | 2022-01-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.6900 | 22,707 | 106 | 5,063,286 | ||||
| 2022-01-25 | 2022-01-21 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.9400 | 24,703 | 122 | 5,040,579 | ||||
| 2022-01-21 | 2022-01-20 | 4 | Peyer James | SNSE | Common Stock | I | 5.1700 | 20,000 | 103 | 5,015,876 | ||||
| 2022-01-21 | 2022-01-19 | 4 | Peyer James | SNSE | Common Stock | I | 4.9700 | 10,244 | 51 | 4,995,876 | ||||
| 2022-01-21 | 2022-01-20 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.1700 | 20,000 | 103 | 5,015,876 | ||||
| 2022-01-21 | 2022-01-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.9700 | 10,244 | 51 | 4,995,876 | ||||
| 2022-01-20 | 2022-01-18 | 4 | Peyer James | SNSE | Common Stock | I | 5.0800 | 10,000 | 51 | 4,985,632 | ||||
| 2022-01-20 | 2022-01-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.0800 | 10,000 | 51 | 4,985,632 | ||||
| 2022-01-18 | 2022-01-14 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.9900 | 6,219 | 31 | 4,975,632 | ||||
| 2022-01-18 | 2022-01-13 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.1300 | 19,953 | 102 | 4,969,413 | ||||
| 2022-01-18 | 2022-01-14 | 4 | Peyer James | SNSE | Common Stock | I | 4.9900 | 6,219 | 31 | 4,975,632 | ||||
| 2022-01-18 | 2022-01-13 | 4 | Peyer James | SNSE | Common Stock | I | 5.1300 | 19,953 | 102 | 4,969,413 | ||||
| 2022-01-13 | 2022-01-12 | 4 | Peyer James | SNSE | Common Stock | I | 5.2200 | 9,202 | 48 | 4,949,460 | ||||
| 2022-01-13 | 2022-01-11 | 4 | Peyer James | SNSE | Common Stock | I | 5.1800 | 10,845 | 56 | 4,940,258 | ||||
| 2022-01-13 | 2022-01-12 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2200 | 9,202 | 48 | 4,949,460 | ||||
| 2022-01-13 | 2022-01-11 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.1800 | 10,845 | 56 | 4,940,258 | ||||
| 2022-01-11 | 2022-01-10 | 4 | Peyer James | SNSE | Common Stock | I | 5.2800 | 10,000 | 53 | 4,929,413 | ||||
| 2022-01-11 | 2022-01-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2800 | 10,000 | 53 | 4,929,413 | ||||
| 2022-01-03 | 2021-12-30 | 4 | Peyer James | SNSE | Common Stock | I | 4.8500 | 1,127 | 5 | 4,919,413 | ||||
| 2022-01-03 | 2021-12-30 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.8500 | 1,127 | 5 | 4,919,413 | ||||
| 2021-12-30 | 2021-12-29 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.9800 | 69,000 | 344 | 4,918,286 | ||||
| 2021-12-30 | 2021-12-29 | 4 | Peyer James | SNSE | Common Stock | I | 4.9800 | 69,000 | 344 | 4,918,286 | ||||
| 2021-12-29 | 2021-12-28 | 4 | Peyer James | SNSE | Common Stock | I | 5.2800 | 11,288 | 60 | 4,849,286 | ||||
| 2021-12-29 | 2021-12-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2800 | 11,288 | 60 | 4,849,286 | ||||
| 2021-12-27 | 2021-12-27 | 4 | Peyer James | SNSE | Common Stock | I | 5.3000 | 3,712 | 20 | 4,837,998 | ||||
| 2021-12-27 | 2021-12-27 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.3000 | 3,712 | 20 | 4,837,998 | ||||
| 2021-12-23 | 2021-12-23 | 4 | Peyer James | SNSE | Common Stock | I | 5.2700 | 11,000 | 58 | 4,834,286 | ||||
| 2021-12-23 | 2021-12-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2700 | 11,000 | 58 | 4,834,286 | ||||
| 2021-12-21 | 2021-12-17 | 4 | Peyer James | SNSE | Common Stock | I | 5.2900 | 117 | 1 | 4,823,286 | ||||
| 2021-12-21 | 2021-12-17 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2900 | 117 | 1 | 4,823,286 | ||||
| 2021-12-20 | 2021-12-16 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5.2500 | 10,925 | 57 | 4,823,169 | ||||
| 2021-12-20 | 2021-12-16 | 4 | Peyer James | SNSE | Common Stock | I | 5.2500 | 10,925 | 57 | 4,823,169 | ||||
| 2021-12-13 | 2021-12-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 5.8600 | 20,000 | 117 | 341,769 | ||||
| 2021-12-13 | 2021-12-09 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 6.6200 | 20,000 | 132 | 321,769 | ||||
| 2021-08-12 | 2021-08-11 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7.3436 | -16,030 | -118 | 0 | ||||
| 2021-08-10 | 2021-08-10 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7.1289 | -66,350 | -473 | 16,030 | ||||
| 2021-08-10 | 2021-08-09 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7.0603 | -6,982 | -49 | 82,380 | ||||
| 2021-08-10 | 2021-08-06 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7.1127 | -6,460 | -46 | 89,362 | ||||
| 2021-08-10 | 3/A | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 95,822 | ||||||||
| 2021-08-02 | 2021-07-30 | 4 | Humer Kristian | SNSE | Stock Option (Right to Buy) | D | 7.89 | 16,667 | 16,667 | |||||
| 2021-05-06 | 2021-05-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12.0000 | 350 | 4 | 4,812,244 | ||||
| 2021-05-06 | 2021-05-05 | 4 | Peyer James | SNSE | Common Stock | I | 12.0000 | 350 | 4 | 4,812,244 | ||||
| 2021-04-21 | 2021-04-20 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12.7700 | 385 | 5 | 4,811,894 | ||||
| 2021-04-21 | 2021-04-20 | 4 | Peyer James | SNSE | Common Stock | I | 12.7700 | 385 | 5 | 4,811,894 | ||||
| 2021-04-20 | 2021-04-19 | 4 | Peyer James | SNSE | Common Stock | I | 13.3800 | 1,965 | 26 | 4,811,509 | ||||
| 2021-04-20 | 2021-04-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13.3800 | 1,965 | 26 | 4,811,509 | ||||
| 2021-04-14 | 2021-04-13 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.0000 | 2,000 | 28 | 4,809,544 | ||||
| 2021-04-14 | 2021-04-13 | 4 | Peyer James | SNSE | Common Stock | I | 14.0000 | 2,000 | 28 | 4,809,544 | ||||
| 2021-04-08 | 2021-04-07 | 4 | Peyer James | SNSE | Common Stock | I | 14.0000 | 2,000 | 28 | 4,807,544 | ||||
| 2021-04-08 | 2021-04-07 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.0000 | 2,000 | 28 | 4,807,544 | ||||
| 2021-04-05 | 2021-04-01 | 4 | English Jessie | SNSE | Stock Option (Right to Buy) | D | 14.42 | 16,667 | 16,667 | |||||
| 2021-04-02 | 2021-04-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.0000 | 1,000 | 14 | 4,805,544 | ||||
| 2021-04-02 | 2021-04-01 | 4 | Peyer James | SNSE | Common Stock | I | 14.0000 | 1,000 | 14 | 4,805,544 | ||||
| 2021-03-31 | 2021-03-30 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12.0000 | 2,000 | 24 | 4,804,544 | ||||
| 2021-03-31 | 2021-03-30 | 4 | Peyer James | SNSE | Common Stock | I | 12.0000 | 2,000 | 24 | 4,804,544 | ||||
| 2021-03-25 | 2021-03-24 | 4 | Peyer James | SNSE | Common Stock | I | 14.1200 | 3,750 | 53 | 4,802,544 | ||||
| 2021-03-25 | 2021-03-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.1200 | 3,750 | 53 | 4,802,544 | ||||
| 2021-03-24 | 2021-03-23 | 4 | Peyer James | SNSE | Common Stock | I | 14.3400 | 10,000 | 143 | 4,798,794 | ||||
| 2021-03-24 | 2021-03-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.3400 | 10,000 | 143 | 4,798,794 | ||||
| 2021-03-23 | 2021-03-22 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.0200 | 2,183 | 33 | 4,788,794 | ||||
| 2021-03-23 | 2021-03-22 | 4 | Peyer James | SNSE | Common Stock | I | 15.0200 | 2,183 | 33 | 4,788,794 | ||||
| 2021-03-19 | 2021-03-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.2500 | 817 | 12 | 4,786,611 | ||||
| 2021-03-19 | 2021-03-18 | 4 | Peyer James | SNSE | Common Stock | I | 15.2500 | 817 | 12 | 4,786,611 | ||||
| 2021-03-10 | 2021-03-08 | 4 | Peyer James | SNSE | Common Stock | I | 15.2490 | 1,000 | 15 | 4,785,794 | ||||
| 2021-03-10 | 2021-03-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.2490 | 1,000 | 15 | 4,785,794 | ||||
| 2021-03-08 | 2021-03-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13.7500 | 8,000 | 110 | 4,784,794 | ||||
| 2021-03-08 | 2021-03-05 | 4 | Peyer James | SNSE | Common Stock | I | 13.7500 | 8,000 | 110 | 4,784,794 | ||||
| 2021-03-05 | 2021-03-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14.1250 | 2,000 | 28 | 4,776,794 | ||||
| 2021-03-05 | 2021-03-03 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.8500 | 3,000 | 48 | 4,774,794 | ||||
| 2021-03-05 | 2021-03-04 | 4 | Peyer James | SNSE | Common Stock | I | 14.1250 | 2,000 | 28 | 4,776,794 | ||||
| 2021-03-05 | 2021-03-03 | 4 | Peyer James | SNSE | Common Stock | I | 15.8500 | 3,000 | 48 | 4,774,794 | ||||
| 2021-03-03 | 2021-03-02 | 4 | Peyer James | SNSE | Common Stock | I | 16.2500 | 3,000 | 49 | 4,771,794 | ||||
| 2021-03-03 | 2021-03-02 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16.2500 | 3,000 | 49 | 4,771,794 | ||||
| 2021-03-02 | 2021-02-26 | 4 | Peyer James | SNSE | Common Stock | I | 16.2500 | 5,000 | 81 | 4,768,794 | ||||
| 2021-03-02 | 2021-02-26 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16.2500 | 5,000 | 81 | 4,768,794 | ||||
| 2021-02-26 | 2021-02-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15.7900 | 12,000 | 189 | 4,763,794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18.4200 | 900 | 17 | 4,751,794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16.8400 | 18,100 | 305 | 4,750,894 | ||||
| 2021-02-26 | 2021-02-25 | 4 | Peyer James | SNSE | Common Stock | I | 15.7900 | 12,000 | 189 | 4,763,794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 18.4200 | 900 | 17 | 4,751,794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 16.8400 | 18,100 | 305 | 4,750,894 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18.1000 | 14,300 | 259 | 4,732,794 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 17.0400 | 6,000 | 102 | 4,718,494 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 18.1000 | 14,300 | 259 | 4,732,794 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 17.0400 | 6,000 | 102 | 4,718,494 | ||||
| 2021-02-24 | 2021-02-22 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18.8800 | 9,802 | 185 | 4,712,494 | ||||
| 2021-02-24 | 2021-02-22 | 4 | Peyer James | SNSE | Common Stock | I | 18.8800 | 9,802 | 185 | 4,712,494 | ||||
| 2021-02-23 | 2021-02-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19.7700 | 11,786 | 233 | 4,702,692 | ||||
| 2021-02-23 | 2021-02-19 | 4 | Peyer James | SNSE | Common Stock | I | 19.7700 | 11,786 | 233 | 4,702,692 | ||||
| 2021-02-19 | 2021-02-18 | 4 | Peyer James | SNSE | Common Stock | I | 19.7500 | 753 | 15 | 4,690,906 | ||||
| 2021-02-19 | 2021-02-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19.7500 | 753 | 15 | 4,690,906 | ||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Series BB Preferred Convertible Stock | I | -3,037,849 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Series AA Preferred Convertible Stock | I | -11,447,156 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 301,769 | 301,769 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James See footnotes | SNSE | Series BB Preferred Convertible Stock | I | -4,821,996 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James | SNSE | Series AA Preferred Convertible Stock | I | -110,729,827 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James | SNSE | Common Stock | I | 2,407,328 | 4,690,153 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | H&S INVESTMENTS I LP | SNSE | Series AA Convertible Preferred Stock | D | -209,368,245 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | H&S INVESTMENTS I LP | SNSE | Common Stock | D | 4,361,835 | 4,425,998 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Series BB Preferred Convertible Stock | D | -4,821,996 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Series AA Preferred Convertible Stock | D | -110,729,827 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 2,407,328 | 4,690,153 | ||||||
| 2021-02-05 | 2021-02-03 | 4 | Vojta Deneen | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | RICKS THOMAS G | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Holmen Bob | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Peyer James | SNSE | Stock Option (Right to Buy) | I | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Fjaellskog Marie-Louise | SNSE | Stock Option (Right to Buy) | D | 19.00 | 79,166 | 79,166 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Hoey Anupama | SNSE | Stock Option (Right to Buy) | D | 19.00 | 83,333 | 83,333 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Colgan Erin | SNSE | Stock Option (Right to Buy) | D | 19.00 | 52,083 | 52,083 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Celebi John | SNSE | Stock Option (Right to Buy) | D | 19.00 | 416,666 | 416,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Broder Samuel | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Cambrian BioPharma Inc | SNSE | Stock Option (Right to Buy) | D | 19.00 | 16,666 | 16,666 | |||||
| 2021-02-03 | 3 | Pierce Robert Hamilton | SNSE | Common Stock | D | 73,463 | ||||||||
| 2021-02-03 | 3 | Holmen Bob | SNSE | Common Stock | D | 16,666 | ||||||||
| 2021-02-03 | 3 | Peyer James | SNSE | Common Stock | I | 2,282,825 | ||||||||
| 2021-02-03 | 3 | SAMUELI SUSAN | SNSE | Common Stock | D | 64,163 | ||||||||
| 2021-02-03 | 3 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 2,282,825 |
P
Pasaran terbuka atau pembelian persendirian sekuriti bukan derivatif atau derivatif
S
Pasaran terbuka atau jualan persendirian sekuriti bukan derivatif atau derivatif
A
Pemberian, penganugerahan atau pemerolehan lain sekuriti daripada syarikat (seperti opsyen)
C
Penukaran derivatif
D
Penjualan atau pemindahan sekuriti kembali kepada syarikat
F
Pembayaran harga pelaksanaan atau liabiliti cukai menggunakan sebahagian daripada sekuriti yang diterima daripada syarikat
G
Hadiah sekuriti oleh atau kepada orang dalam
K
Swap ekuiti dan urus niaga lindung nilai yang serupa
M
Pelaksanaan atau penukaran sekuriti derivatif yang diterima daripada syarikat (seperti opsyen)
V
Transaksi dilaporkan secara sukarela pada Borang 4
J
Lain-lain (disertai dengan nota kaki yang menerangkan transaksi)
